Story thread · 2 reports / 2 sources
RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models
financialpost.com · 6d
Investigators Present Data Supporting Disease-Modifying Potential of the Io Therapeutics RXR Agonist Compound IRX4204 in Parkinson’s Disease SPRING, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas, announced today the presentation of new research demonstrating that IRX4204, the company’s phase II clinical stage highly selective […]
First report: RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models — markets.businessinsider.com, 6d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.